ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

The MarketWatch News Department was not involved in the creation of this content. PALO ALTO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX) ...

The product is expected to be available in the first half of 2026. The Food and Drug Administration (FDA) has approved Bondlido ® (lidocaine topical system 10%) for the relief of pain associated with ...

Gel manicures are out in most of Europe. The European Union this month banned a key chemical used in gel nail polish that makes manicures last longer. But why are such manicures and nail polish still ...

An unusual way to deliver drugs gives new meaning to the term “Jell-O shot.” Injected into rats, a water-based gel mixed with the key ingredients in Ozempic or Mounjaro offered long-lasting diabetes ...

Poisonings and deaths linked to the use of the local anesthetic lidocaine have nearly tripled in the US over the past decade, finds an analysis of National Poison Data System (NPDS) reports, published ...

The Board of Directors has approved a deferral of the record date for the dividend, allowing for potential strategic adjustments that may benefit the company and its stakeholders. This move indicates ...

A new fast-acting topical gel could soon replace such drugs, however, potentially reducing unpleasant side effects. One of the challenges with middle ear infections lies in the fact that the infected ...

Ear infections are a common and painful occurrence in infants and toddlers. Oral antibiotics are often prescribed for a week to treat the condition, but these drugs can trigger side effects that ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients with advanced colorectal cancer who were treated with an epidermal growth ...